{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:02:54Z","timestamp":1786719774996,"version":"build-2736575974"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"32","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100024591","name":"National Institute of Pharmaceutical Education and Research, Kolkata","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A site-selective fluoroacylation of pyrazolo[1,5-a]pyrimidines using tri\/difluoroacetic anhydrides (DFAA\/TFAA) under catalyst-free conditions was devised. This method entails a free radical-directed C\u2013H functionalization, delivering a broad range of fluorinated pyrazolo[1,5-a]pyrimidine frameworks, which are valuable key intermediates in pharmaceutical APIs. In addition, this protocol was also applied in the concise synthesis of the zaleplon and reversan drugs.<\/jats:p>","DOI":"10.1021\/acs.joc.6c01094","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:34:54Z","timestamp":1785854094000},"page":"10991-10998","source":"Crossref","is-referenced-by-count":0,"title":["Radical Fluoroacylation\nof Pyrazolo[1,5-\n                    <i>a<\/i>\n                    ]pyrimidines: A Gateway to\nZaleplon and Reversan Drugs"],"prefix":"10.1021","volume":"91","author":[{"given":"Akshay","family":"Kumawat","sequence":"first","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashapal","family":"Basannavar","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Sravani","family":"Galla","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshirsagar Prasad","family":"Suhas","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Dastari","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagula","family":"Shankaraiah","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research (NIPER) , , ,","place":["Hyderabad, India, 500037"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"7","key":"2026081410101806500_cit1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1039\/D0CS01466D","article-title":"En route sustainability: metal-free\nC\u2013H bond functionalisation","volume":"52","author":"Roy","year":"2023","journal-title":"Chem. Soc.\nRev."},{"issue":"14","key":"2026081410101806500_cit2","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1039\/D1CS00242B","article-title":"Molecular oxygen-mediated oxygenation\nreactions involving radicals","volume":"50","author":"Tang","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"5846","key":"2026081410101806500_cit3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: looking\nbeyond intuition","volume":"317","author":"Mu\u0308ller","year":"2007","journal-title":"Science"},{"issue":"14","key":"2026081410101806500_cit4","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine\nand fluorinated motifs in the design and application of bioisosteres\nfor drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"issue":"14","key":"2026081410101806500_cit5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30143009","article-title":"The role of trifluoromethyl and trifluoromethoxy groups\nin medicinal chemistry: implications for drug design","volume":"30","author":"Nova\u0301s","year":"2025","journal-title":"Molecules"},{"issue":"14","key":"2026081410101806500_cit6","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.1039\/D1CS00360G","article-title":"Late-stage\ndifluoromethylation: concepts,\ndevelopments and perspective","volume":"50","author":"Sap","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"15","key":"2026081410101806500_cit7","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1021\/jm800219f","article-title":"The many\nroles for fluorine in medicinal chemistry","volume":"51","author":"Hagmann","year":"2008","journal-title":"J.\nMed. Chem."},{"issue":"2","key":"2026081410101806500_cit8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1039\/B711844A","article-title":"Understanding\norganofluorine chemistry: an introduction to the C\u2013F bond","volume":"37","author":"O\u2019Hagan","year":"2008","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"2026081410101806500_cit9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in\nmedicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem. Soc. Rev."},{"issue":"21","key":"2026081410101806500_cit10a","doi-asserted-by":"publisher","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications\nof fluorine in medicinal\nchemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026081410101806500_cit10b","doi-asserted-by":"publisher","DOI":"10.1002\/ajoc.70344","article-title":"Visible-light\nmediated one-pot synthesis of pyrazolo[3,4-b]pyridines via intramolecular rearrangement","volume":"15","author":"Singitham","year":"2026","journal-title":"Asian J. Org. Chem."},{"issue":"21","key":"2026081410101806500_cit11","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1021\/ol0519745","article-title":"Pyrazolo[1,5-a]pyridines as p38 kinase\ninhibitors","volume":"7","author":"Stevens","year":"2005","journal-title":"Org. Lett."},{"issue":"19","key":"2026081410101806500_cit12","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1016\/j.bmcl.2009.08.009","article-title":"Pyrazolopyrimidines\nand pyrazolotriazines\nwith potent activity against herpesviruses","volume":"19","author":"Gudmundsson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026081410101806500_cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107867","article-title":"Pyrrolo [2,\n3-d] pyrimidines as potential kinase inhibitors in\ncancer drug discovery: a critical review","volume":"153","author":"Madhurya","year":"2024","journal-title":"Bioorg.\nChem."},{"issue":"7","key":"2026081410101806500_cit14a","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1021\/acsmedchemlett.5b00485","article-title":"Discovery of pyrazolo[1,5-a]pyrimidine TTK inhibitors: CFI-402257 as a potent anticancer\nagent","volume":"7","author":"Liu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"24","key":"2026081410101806500_cit14b","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1021\/jm100732t","article-title":"A pyrazolo[1,5-a]pyrimidine as CDK inhibitor with\nantitumor activity","volume":"53","author":"Heathcote","year":"2010","journal-title":"J. Med. Chem."},{"issue":"14","key":"2026081410101806500_cit15","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1021\/jm100350r","article-title":"Pyrazolo[1,5-a]pyrimidin-2-yl amines\nas 5-HT6 antagonists","volume":"53","author":"Ivachtchenko","year":"2010","journal-title":"J. Med. Chem."},{"issue":"15","key":"2026081410101806500_cit16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29153560","article-title":"Pyrazolo[1,5-a]pyrimidine as a framework for Trk inhibitors","volume":"29","author":"Mahajan","year":"2024","journal-title":"Molecules"},{"key":"2026081410101806500_cit17","first-page":"1392","article-title":"Sur une me\u0301thode ge\u0301ne\u0301rale\nde synthe\u0300se\nd\u2019hydrocarbures","volume":"84","author":"Friedel","year":"1877","journal-title":"C. R. Acad. Sci."},{"issue":"15","key":"2026081410101806500_cit18","doi-asserted-by":"publisher","first-page":"9839","DOI":"10.1021\/acs.joc.2c00881","article-title":"BF3-mediated acetylation\nof pyrazolo[1,5-a]pyrimidines","volume":"87","author":"Aranzazu","year":"2022","journal-title":"J. Org. Chem."},{"issue":"28","key":"2026081410101806500_cit19","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1039\/C7OB01335C","article-title":"Copper-mediated\ntrifluoroacetylation of indoles","volume":"15","author":"Yan","year":"2017","journal-title":"Org. Biomol.\nChem."},{"issue":"38","key":"2026081410101806500_cit20","doi-asserted-by":"publisher","first-page":"31088","DOI":"10.1039\/D5RA03638K","article-title":"Eco-friendly Friedel\u2013Crafts\nacylation of arenes","volume":"15","author":"Cherif","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"2026081410101806500_cit21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/A:1013829215544","article-title":"Catalytic\nFriedel\u2013Crafts acylation\nof heteroaromatics","volume":"19","author":"Komoto","year":"2002","journal-title":"Top. Catal."},{"issue":"18","key":"2026081410101806500_cit22","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1021\/acs.orglett.0c02484","article-title":"BF3\u00b7OEt2-mediated tetra-functionalization\nof amino acids","volume":"22","author":"Karuppusamy","year":"2020","journal-title":"Org. Lett."},{"issue":"5","key":"2026081410101806500_cit23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2174\/157017910792246126","article-title":"Trifluoroacetylation\nin organic synthesis","volume":"7","author":"Lo\u0301pez","year":"2010","journal-title":"Curr. Org. Synth."},{"key":"2026081410101806500_cit24a","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1021\/acs.orglett.5c01608","article-title":"Flexible synthesis\nof substituted pyridines bearing fluoroalkyl groups","volume":"27","author":"Li","year":"2025","journal-title":"Org. Lett."},{"issue":"24","key":"2026081410101806500_cit24b","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1021\/acs.orglett.7b03291","article-title":"Scalable synthesis\nof trifluoromethylated heterocycles","volume":"19","author":"Schafer","year":"2017","journal-title":"Org. Lett."},{"issue":"35","key":"2026081410101806500_cit24c","doi-asserted-by":"publisher","first-page":"15969","DOI":"10.1021\/jacs.2c03618","article-title":"Detection\nof short-lived radical intermediates","volume":"144","author":"Williams","year":"2022","journal-title":"J. Am.\nChem. Soc."},{"issue":"7","key":"2026081410101806500_cit25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1021\/ja00475a040","article-title":"Lanthanides\nin organic chemistry: selective reductions","volume":"100","author":"Luche","year":"1978","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"2026081410101806500_cit26","first-page":"3242","article-title":"Reversan as\nan MRP1 inhibitor","volume":"68","author":"Burkhart","year":"2008","journal-title":"Cancer Res."},{"issue":"12","key":"2026081410101806500_cit27","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1021\/acsabm.3c00644","article-title":"Reversal of multidrug resistance\nby reversan","volume":"6","author":"Hasan","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"key":"2026081410101806500_cit28","first-page":"115","article-title":"Clinical evaluation of zaleplon in insomnia","author":"Ebbens","year":"2010","journal-title":"Nat. Sci. Sleep"}],"container-title":["The Journal of Organic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.joc.6c01094","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/joceah\/article-pdf\/91\/32\/10991\/66353668\/acs.joc.6c01094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/joceah\/article-pdf\/91\/32\/10991\/66353668\/acs.joc.6c01094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:20:36Z","timestamp":1786717236000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/joceah\/article\/91\/32\/10991\/5238265\/Radical-Fluoroacylation-of-Pyrazolo-1-5-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":32,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2026,8,1]]},"published-print":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.joc.6c01094","relation":{},"ISSN":["0022-3263","1520-6904"],"issn-type":[{"value":"0022-3263","type":"print"},{"value":"1520-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}